Skip to main content
Publications
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Lytras T, Beckmeyer-Borowko A, Kogevinas M, Kromhout H, Carsin AE, Anto JM, Bentouhami H, Weyler J, Heinrich J, Nowak D, Urrutia I, Martinez-Moratalla J, Gullon JA, Pereira Vega A, Raherison Semjen C, Pin I, Demoly P, Leynaert B, Villani S, Gislason T, Svanes O, Holm M, Forsberg B, Norback D, Mehta AJ, Keidel D, Vernez D, Benke G, Jogi D, Toren K, Sigsgaard T, Schlunssen V, Olivieri M, Blanc PD, Watkins J, Bono R, Squillacioti G, Buist AS, Vermeulen R, Jarvis D, Probst-Hensch N, Zock JP. Cumulative occupational exposures and lung-function decline in two large general-population cohorts. Ann Am Thorac Soc. 2021 Feb;18(2):238-46. doi: 10.1513/AnnalsATS.202002-113OC
Anthony L, Horsch D, Ervin C, Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews. Poster presented at the 2016 UKI NETS 14th National Conference; December 2016. London, UK. [abstract] Pancreas. 2016 Dec; 45(3):470. Previously presented at the 8th Symposium of the North American Neuroendocrine Tumor Society. doi: 10.1530/endoabs.46.P11